HWGB BIOTECH SDN BHD
Healthcare
This wholly owned subsidiary of HWGB Group is primarily involved in the distribution of biotechnology products, bioinformatics diagnostic tools, medical engineering equipment and its software developments and tools, as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
Most recently, as part of the investment with another HWGB Group subsidiary company, HWG Capital, HWGB Biotech has entered into a third supplemental joint venture agreement (JVA) with E-MO Biology Inc (EBI), in funding the research and development of vaccines, immunological treatment and diagnostic product development in relation to the COVID-19 virus. To date, EBI’s vaccine clinical project has been granted full approval from the Food and Drug Administration in the United States (FDA) for its Phase IV clinical trial, and the research is also published officially on the World Health Organisation’s (WHO) official clinical research website.
Visit website: https://www.hwgbbiotech.com/
